SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 ------------ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 18, 2004 Eyetech Pharmaceuticals, Inc. ------------------------------------------------------------------------- (Exact Name of Registrant as Specified in Charter) Delaware 000-50516 13-4104684 ---------------------------- -------------- ------------------- (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) File Numbers) Identification No.) 3 Times Square, 12th Floor New York, NY 10036 ------------------------------------------------ ------------------- (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (212) 824-3100 ------------------------------------------------------------------------- (Former name or former address, if changed since last report) ITEM 5. OTHER EVENTS On June 18, 2004, Eyetech Pharmaceuticals, Inc. announced the appointment of Michael J. Regan to the Board of Directors of Eyetech. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 18, 2004 EYETECH PHARMACEUTICALS, INC. By: /s/ Glenn P. Sblendorio -------------------------------- Name: Glenn P. Sblendorio Title: Senior Vice President, Finance and Chief Financial Officer EXHIBIT INDEX Exhibit No. Description ----------- ----------- 99.1 Press release dated June 18, 2004 announcing the appointment of Michael J. Regan to its Board of Directors.